• Your tax rate just dropped. Here is exactly how much more you will take home from 1 July

    A person using a calculator.

    Something changed in every Australian worker’s pay packet this week.

    From 1 July 2026, the tax rate on income between $18,201 and $45,000 dropped from 16% to 15%. This delivered a tax cut to almost every Australian taxpayer regardless of income level.

    The cut is applied automatically through your employer’s payroll. You do not need to do anything to receive it.

    The actual dollar amount

    The size of the benefit depends on how much of your income falls in the $18,201 to $45,000 bracket.

    For someone earning exactly $45,000, the benefit from this round of cuts alone is approximately $268 per year, or around $5.15 per week.

    For someone earning above $45,000, the benefit is also $268, since the portion of income taxed at the lower rate also receives this benefit.

    However, the government’s total tax cuts since 2024 are larger than this single round.

    An average earner on $81,245 will receive $1,978 in total tax cuts in FY27 compared to 2023-24 settings, when all three rounds of legislated tax cuts are combined.

    That is $38 per week more in take-home pay than two years ago.

    From 1 July 2027, the same bracket rate drops again to 14%, adding an additional maximum of $268 per year in tax savings.

    The $1,000 instant tax deduction

    Alongside the rate cut, a new $1,000 instant tax deduction for work-related expenses starts this financial year.

    Previously, workers could only claim up to $300 in work-related expenses without providing receipts.

    From FY27, that cap rises to $1,000, meaning workers can reduce their taxable income by up to $1,000 from the first dollar of work expenses without keeping a single receipt.

    For a worker paying the 32.5% marginal rate, claiming the full $1,000 deduction is worth approximately $325 in tax savings when they lodge their FY27 tax return.

    The deduction does not apply to FY26 returns lodged from 1 July 2026. But it does apply to FY27.

    What to do with the extra money

    A tax cut of $268 per year is not life-changing.

    But small, consistent amounts invested over time compound into meaningful outcomes.

    An extra $268 per year invested into the share market, earning the historical ASX 200 average of approximately 8.5% per annum, grows to approximately $13,400 over 20 years.

    For investors who want to put their tax saving to work immediately, Commonwealth Bank of Australia (ASX: CBA) remains one of the most widely held ASX shares among Australian retail investors. CBA shares offer a fully franked dividend yield and long-term earnings track record that suits a small, consistent investment approach.

    Foolish takeaway for your tax bill

    Your tax rate dropped on 1 July 2026.

    The cut is small, worth up to $268 this year and $536 from 2027. But combined with the new $1,000 instant tax deduction, FY27 is meaningfully less taxing than FY26 was.

    The smartest move is to direct that saving somewhere productive rather than letting it disappear into the household budget unnoticed.

    The post Your tax rate just dropped. Here is exactly how much more you will take home from 1 July appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Commonwealth Bank Of Australia right now?

    Before you buy Commonwealth Bank Of Australia shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Commonwealth Bank Of Australia wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Why I want to own these ASX shares brokers rate as buys

    Broker looking at the share price on her laptop with green and red points in the background.

    Sometimes the market focuses heavily on short-term problems and misses the long-term potential of a business. That is where broker research can uncover interesting ASX opportunities.

    While analysts can be wrong, their work can highlight businesses where the market may be underestimating future growth.

    Three ASX shares that have recently caught my attention are named below.

    ResMed Inc. (ASX: RMD)

    The first ASX share I would consider buying is one where the market appears to have become much more cautious.

    ResMed shares are trading around $31.44, and Morgans believes the recent weakness has created an attractive opportunity.

    The concerns are understandable. Investors have been weighing the potential impact of GLP-1 therapies, the possibility of Philips returning to the US PAP market, and broader weakness across healthcare shares.

    However, I think the bigger picture remains compelling. ResMed operates in a healthcare market with a huge long-term opportunity. Sleep apnoea and related breathing disorders affect a large number of people globally, and many remain undiagnosed or untreated. That creates a significant runway for growth.

    I also like the direction of the business beyond traditional devices. Connected technology, digital health solutions, and software can help improve patient outcomes while making treatment more accessible.

    Morgans highlighted that ResMed has de-rated to around 16 times forward earnings, close to its lowest valuation since the post-GFC period, while consensus still expects double-digit earnings growth. For this reason, it has a buy recommendation and $41.72 target price on its shares.

    The risks are real, but I think the market may be underestimating the quality of the underlying business.

    Flight Centre Travel Group Ltd (ASX: FLT)

    The second opportunity comes from a business that has been caught up in broader travel uncertainty.

    Flight Centre shares have struggled as investors assess the impact of geopolitical issues and weaker operating conditions.

    But I think the long-term travel story remains attractive. People continue to value experiences, holidays, and international travel. When confidence improves, travel demand can recover quickly.

    What interests me about Flight Centre is the strength of its position. The company has built a global travel network, strong brand recognition, and a valuable customer base. It also has a strong balance sheet.

    Morgans believes the recent weakness creates an opportunity, highlighting the company’s financial strength and the potential for a stronger recovery in the second half of FY27. It has a buy recommendation and $14.80 target price on the shares.

    I think the key is patience. The recovery may take time, but if travel conditions normalise, earnings and the share price could respond positively.

    Sigma Healthcare Ltd (ASX: SIG)

    The final ASX share I would look at is Chemist Warehouse owner Sigma Healthcare.

    Ord Minnett believes the company’s UK expansion opportunity could become significant over time. The initial rollout is still small, but the market itself is large and fragmented, creating an opportunity for a proven retail model to expand.

    What I find interesting is the possibility of taking existing capabilities into a new market. Sigma has access to pharmacy infrastructure, retail experience, and the backing of one of Australia’s strongest consumer brands through Chemist Warehouse.

    There is execution risk, as with any international expansion. But I think the potential upside comes from the ability to replicate a successful model in a much larger market.

    Ord Minnett recently placed a buy recommendation and $3.40 target price on the shares. I think this is a fair valuation and shows potential for good returns from its current share price of around $2.82.

    Foolish takeaway

    I think these three ASX shares are interesting because investors are currently looking beyond the headlines and asking whether the long-term opportunity has changed.

    In my view, the businesses themselves still have attractive qualities. The challenge for investors is having the patience to wait for those strengths to become more visible.

    The post Why I want to own these ASX shares brokers rate as buys appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Flight Centre Travel Group right now?

    Before you buy Flight Centre Travel Group shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Flight Centre Travel Group wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Flight Centre Travel Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • What is Bell Potter saying about A2 Milk shares after its results?

    A little girl brings her mug of hot milk close to her mouth, ready to take a big sip.

    Yesterday, a2 Milk Co Ltd (ASX: A2M) released its FY26 results.

    As Laura Stewart reported yesterday, the company reported preliminary FY26 results, featuring revenue up more than 12% to about $1.97 billion. 

    This was despite China infant milk formula (IMF) sales declining due to supply chain disruptions.

    Key results included: 

    • FY26 revenue of approximately $1.97 billion, up over 12% year-over-year
    • China label IMF sales down around 14% on FY25 after supply chain issues in 4Q26
    • EBITDA margin expected at the high end of 14.0% to 14.5% guidance
    • NPAT anticipated to be slightly up on FY25, with underlying NPAT also rising

    Following the results, A2 Milk shares fell over 4%. 

    What is Bell Potter’s updated outlook on A2 Milk shares?

    Following the results, the team at Bell Potter provided updated guidance on A2 Milk shares. 

    Bell Potter views the update as broadly positive, with revenue expected to land within guidance at $1.97 billion and EBITDA margins at the top end of the guided range, resulting in EBITDA of around $285 million, broadly in line with expectations. 

    Profit guidance has improved, with NPAT now expected to be slightly higher year-on-year and operating cash conversion upgraded to around 70%, reflecting stronger cash generation than previously guided.

    The key disappointment was the weaker-than-expected performance of China label infant formula, with revenue expected to decline 14% year-on-year and second-half sales falling more than 40% after adjusting for foreign exchange, significantly below Bell Potter’s forecasts. 

    While product supply issues have largely been resolved and management is now focused on marketing initiatives to win back former customers and attract new users, Bell Potter believes the weakness suggests the company may need to rebalance its China sales mix in FY27.

    As a result, Bell Potter has modestly increased its FY26 earnings forecast but reduced FY27 and FY28 estimates to reflect higher expected brand investment and a slower recovery in China. 

    NPAT forecasts have been revised up 3% for FY26, but down 6% for FY27 and down 5% for FY28.

    Hold recommendation maintained 

    A2 Milk shares have experienced volatility in 2026, and are currently down nearly 20% year to date. 

    Yesterday, A2 Milk shares closed at $7.37 per share. 

    Bell Potter has maintained its hold recommendation and share price target of $6.90 on the company. 

    This indicates a 6% downside from current levels. 

    The post What is Bell Potter saying about A2 Milk shares after its results? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in A2 Milk right now?

    Before you buy A2 Milk shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and A2 Milk wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.